Is DARE a good stock to buy?

Is DARE a good stock to buy?

The consensus among 2 Wall Street analysts covering (NASDAQ: DARE) stock is to Strong Buy DARE stock.

Similarly, Should I buy or sell DARE stock?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Daré Bioscience stock is Buy based on the current 4 buy ratings for DARE.

What is the DARE stock prediction? Stock Price Forecast

The 5 analysts offering 12-month price forecasts for Dare Bioscience Inc have a median target of 6.00, with a high estimate of 17.00 and a low estimate of 3.00. The median estimate represents a +305.41% increase from the last price of 1.48.

Thereof, What is the stock of DARE Pharma?

(DARE) Stock Price, News, Quote & History – Yahoo Finance.

Performance Outlook.

Previous Close 1.4900
52 Week Range 1.2000 – 2.5100
Volume 6,361,573
Avg. Volume 2,143,816

Is dare Bioscience a buy?

Daré Bioscience has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

When was DARE Stock FDA approved?

Development Timeline for Xaciato

Date Article
Dec 7, 2021 Approval FDA Approves Xaciato (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
Aug 9, 2021 Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis

• 8 déc. 2021

DARE Bioscience price target?

Stock Price Targets

High $17.00
Median $6.00
Low $3.00
Average $7.20
Current Price $1.4100

What is DARE Bioscience FDA approval?

Daré’s New Drug Application (NDA) for XACIATO (clindamycin phosphate) vaginal gel (formerly known as DARE-BV1) was approved by the FDA on December 7, 2021 .

Is DARE Stock FDA approved?

Daré’s New Drug Application (NDA) for XACIATO (clindamycin phosphate) vaginal gel (formerly known as DARE-BV1) was approved by the FDA on December 7, 2021.

Did dare bioscience get FDA approval?

Daré Bioscience Announces FDA Acceptance And Priority Review Of New Drug Application For Dare-Bv1 For The Treatment Of Bacterial Vaginosis.

Is DARE Stock News approved by the FDA?

Dare Bioscience (NASDAQ:DARE) recently rallied 30.0% on the news of FDA approval of XACIATO for bacterial vaginosis in women on Dec. 7, 2021. Since the FDA approval DARE stock price has declined for no fundamental reason other than the stock market weakness.

Is DARE Stock FDA approved?

On December 7, 2021, Daré announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for the treatment of bacterial vaginosis in females 12 years of age and older.

What does dare Bioscience do?

Dare Bioscience, Inc. operates as a healthcare company. The Company offers women’s reproductive health devices, therapeutics, and diagnostics. Dare Bioscience provides contraception, vaginal health, pain, and fertility products.

Can I dare Bioscience bacterial vaginosis?

DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2% designed as a one-time vaginally-administered treatment for bacterial vaginosis.

What is a Pdufa from FDA?

The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products.

What is DARE Bioscience press release?

Press Releases

  • Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022. 03-24-2022.
  • Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference. 03-22-2022.
  • Daré Bioscience to Participate in Upcoming Conferences. 03-02-2022.

What happens on Pdufa date?

In United States pharmaceutical regulatory practice, the PDUFA date is the colloquial name for the date by which the Food and Drug Administration must respond to a New Drug Application or a Biologics License Application.

Who is the CEO of DARE Bioscience?

Sabrina Martucci Johnson. Ms. Johnson founded Daré Bioscience Operations in 2015 and has served as President, CEO and a member of the Board of Directors since its inception and following its business combination with Cerulean Pharma in July 2017, when the Company was renamed Daré Bioscience.

What is the latest news in Dare Bioscience?

Press Releases

  • Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update. …
  • Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)

What is the next dare bioscience event?

Clinical and Scientific Events

  • 09-08-2021 to 09-10-2021. 13th European Congress on Menopause and Andropause. …
  • 07-25-2021 to 07-29-2021. 2021 Controlled Release Society Virtual Annual Meeting. …
  • 03-09-2020. …
  • 10-07-2019 to 10-08-2019. …
  • 08-08-2019 to 08-10-2019. …
  • 07-22-2019 to 07-24-2019.

What is Xaciato?

XACIATO is a lincosamide antibacterial indicated for the. treatment of bacterial vaginosis in female patients 12 years of. age and older. (

What is the difference between BLA and NDA?

Whereas a new drug application (NDA) is used for drugs subject to the drug approval provisions of the FDC Act, a biologics license application (BLA) is required for biological products subject to licensure under the PHS Act. FDA form 356h is used for both NDA and BLA submissions.

Why was PDUFA created?

PDUFA was passed in order to shorten the length of time from a manufacturer’s submission of a New Drug Application or a Biologics License Application to an FDA decision approval or licensure. Congress created three kinds of user fees via PDUFA and required that they each make up one-third of the total fees collected.

How long does BLA approval take?

Review Timeline

As per the Prescription Drug User Fee Act (PDUFA), the FDA agreed to review the majority of BLAs within 10 months of 60 day filing and for the priority submissions it has been cut down to 6 months of 60 day filing date.

Join TheMoney.co community and don’t forget to share this post !

Zeen is a next generation WordPress theme. It’s powerful, beautifully designed and comes with everything you need to engage your visitors and increase conversions.